Genital Herpes Pipeline Analysis: 15+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "Genital Herpes Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Genital Herpes Pipeline Report
• DelveInsight's Genital Herpes Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Genital Herpes treatment.
• The leading Genital Herpes Companies includes Immune System Regulation, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, AiCuris, Admedus Immunotherapies, Agenus Inc., Sanofi, Rational Vaccines, Starpharma, Brandenburg Antiinfektiva GmbH, JN-International Medical Corporation, BlueWillow Biologics, Vaxxit, Nanoviricides, Vaccibody, Vaxart, Biomere, Immune design (acquired by Merck & Co), AlphaVax, RedBioTec, X-Vax Technology, and others are some of the key prominent pharma players working in the domain.
• The promising Genital Herpes Therapies in the pipeline includes HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others are under investigation in different phases of clinical trials for the treatment of Genital Herpes.
• The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital Herpes.

Get an overview of the Genital Herpes Pipeline landscape @ https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Genital Herpes Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes.

Latest Breakthroughs in the Genital Herpes Treatment Landscape
• In May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).
• In June 2020, AiCuris was granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the treatment of HSV infections in immunocompromised patients.

Genital Herpes Emerging Drugs
• Pritelivir: AiCuris
• UB-621: United Biopharma
• HDIT 101: Heidelberg ImmunoTherapeutics

Get to know more information about Genital Herpes treatment therapies @ https://www.delveinsight.com/sample-request/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Genital Herpes Pipeline Therapeutics Analysis
There are approx. 15+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, AiCuris.

DelveInsight's Genital Herpes Pipeline Report covers around 20+ products under different phases of clinical development like-
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about therapy set to grab substantial Genital Herpes Pipeline landscape @ https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Genital Herpes Pipeline Report
• Coverage- Global
• Genital Herpes Companies- Immune System Regulation, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, AiCuris, Admedus Immunotherapies, Agenus Inc., Sanofi, Rational Vaccines, Starpharma, Brandenburg Antiinfektiva GmbH, JN-International Medical Corporation, BlueWillow Biologics, Vaxxit, Nanoviricides, Vaccibody, Vaxart, Biomere, Immune design (acquired by Merck & Co), AlphaVax, RedBioTec, X-Vax Technology, and others
• Genital Herpes Therapies- HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and others
• Genital Herpes Pipeline Assessment by Product Type
• Genital Herpes Pipeline Assessment by Stage and Product Type
• Genital Herpes Pipeline Assessment by Route of Administration
• Genital Herpes Pipeline Assessment by Stage and Route of Administration
• Genital Herpes Pipeline Assessment by Molecule Type
• Genital Herpes Pipeline Assessment by Stage and Molecule Type

Table of Content
1. Introduction
2. Executive Summary
3. Genital Herpes: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Pritelivir: AiCuris
8. Mid Stage Products (Phase II)
9. UB-621: United Biopharma
10. Early stage products (Phase I/II)
11. HSV 2 Vaccines: Sanofi
12. Inactive Products
13. Genital Herpes Key Companies
14. Genital Herpes Key Products
15. Genital Herpes- Unmet Needs
16. Genital Herpes- Market Drivers and Barriers
17. Genital Herpes- Future Perspectives and Conclusion
18. Genital Herpes Analyst Views
19. Genital Herpes Key Companies
20. Appendix

Got Queries? Reach out for more information on the Genital Herpes Pipeline Report @ https://www.delveinsight.com/report-store/genital-herpes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.